MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.24.00184

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.

Shaffer Brian C, Gooptu Mahasweta, DeFor Todd E, Maiers Martin, Bolaños-Meade Javier, Abboud Ramzi, Briggs Adrienne D, Khimani Farhad, Modi Dipenkumar, Newcomb Richard, Shpall Elizabeth J, Bupp Caitrin, Spellman Stephen R, Stefanski Heather E, Shaw Bronwen E, Auletta Jeffery J, Devine Steven M, Jimenez Jimenez Antonio M, Al Malki Monzr M

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)-based prophylaxis.METHODSThree-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021.RESULTSIncluded were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syndromes (29.2%). Median patient age was 60.7 years (range, 18.0-82.7) and median follow-up was 36.6 (range, 3.0-77.8) months. When compared with MUD HCT with PTCy, MMUD HCT with PTCy had similar OS (hazard ratio [HR], 0.96 [95% CI, 0.823 to 1.11]; P = .60) and GRFS (HR, 0.90 [0.79 to 1.02]; P = .1). When compared with MUD HCT with CNI, OS was improved after MUD HCT with PTCy (HR, 0.88 [0.80 to 0.96]; P = .004) and GRFS was improved with PTCy after either MUD (HR, 0.61 [0.57 to 0.66]; P < .0001) or MMUD (HR, 0.68 [0.60 to 0.76]; P < .0001) HCT. Benefit from PTCy was independent of patient ancestry. Global registry level analysis demonstrated that inclusion of MMUD increased donor availability regardless of recipient ancestry.CONCLUSIONUse of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.

Для цитирования: Shaffer Brian C, Gooptu Mahasweta, DeFor Todd E, Maiers Martin, Bolaños-Meade Javier, Abboud Ramzi, Briggs Adrienne D, Khimani Farhad, Modi Dipenkumar, Newcomb Richard, Shpall Elizabeth J, Bupp Caitrin, Spellman Stephen R, Stefanski Heather E, Shaw Bronwen E, Auletta Jeffery J, Devine Steven M, Jimenez Jimenez Antonio M, Al Malki Monzr M. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. DOI: 10.1200/jco.24.00184.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.